Conditions: Asthma
Keywords: COPD
Allocation: RANDOMIZED | Intervention model: CROSSOVER
Enrollment: 62
Healthy volunteers: no

Brief summary:
The purpose of this study is to evaluate the pharmacodynamics of single doses of inhaled LAS100977 QD in patients with persistent asthma.

Detailed description:

Arms:
arm 1: Single-dose LAS100977 0.625 μg, during double-blind treatment period arm 2: Single-dose LAS100977 1.25 μg, during double-blind treatment period arm 3: Single-dose LAS100977 2.5 μg, during double-blind treatment period arm 4: Single-dose salbutamol 400 μg, during double-blind treatment period arm 5: Placebo to LAS100977, and placebo to salbutamol arm 6: Single-dose LAS100977 0.313 μg, during double-blind treatment period

Interventions: intervention 1: LAS100977 0.313 μg intervention 2: LAS100977 0.625 μg intervention 3: LAS100977 1.25 μg intervention 4: LAS100977 2.5 μg intervention 5: Salbutamol 400 μg intervention 6: Salbutamol placebo intervention 7: LAS100977 placebo
Intervention descriptions: intervention 1: Dry powder inhalation, once-daily, single-dose intervention 2: Dry powder inhalation, once-daily, single-dose intervention 3: Dry powder inhalation, once-daily, single-dose intervention 4: Dry powder inhalation, once-daily, single-dose intervention 5: Pressurized inhalation suspension, once-daily, single-dose intervention 6: Pressurized inhalation, once-daily intervention 7: Dry powder inhalation, once-daily

Protocol document: